A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

The Intra-Aortic Balloon Pump

28.9K views

DOI:

10.3791/62132

February 5th, 2021

In This Article

Summary

We describe the steps for the percutaneous implantation of the intra-aortic balloon pump (IABP), a mechanical circulatory support device. It acts by counterpulsation, inflating at the onset of diastole, augmenting diastolic aortic pressure and improving coronary blood flow and systemic perfusion, and deflating before systole, reducing left ventricular afterload.

Abstract

Cardiogenic shock remains one of the most challenging clinical syndromes in modern medicine. Mechanical support is being increasingly used in the management of cardiogenic shock. Intra-aortic balloon pump (IABP) is one of the earliest and most widely used types of mechanical circulatory support. The device acts by external counterpulsation and uses systolic unloading and diastolic augmentation of aortic pressure to improve hemodynamics. Although IABP provides less hemodynamic support when compared with newer mechanical circulatory support devices, it can still be the mechanical support device of choice in appropriate situations because of its relative simplicity of insertion and removal, need for smaller size vascular access and better safety profile. In this review, we discuss the equipment, procedural and technical aspects, hemodynamic effects, indications, evidence, current status and recent advances in the use of IABP in cardiogenic shock.

Introduction

Cardiogenic shock is a clinical condition characterized by decreased end organ perfusion due to severe cardiac dysfunction. The most widely accepted definition of cardiogenic shock is based on the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock trial (SHOCK)1 and Intra-aortic Balloon Support for Myocardial Infarction with Cardiogenic Shock (IABP-SHOCK-II) trial2 and includes the following parameters:

1. Systolic blood pressure <90 mm Hg for ≥30 min or vasopressor and/or mechanical support to maintain SBP ≥90 mm Hg

2. Evid....

Access restricted. Please log in or start a trial to view this content.

Protocol

This protocol follows the guidelines of institutional human research ethics committee.

1. Pre-insertion preparation

NOTE: The IABP is preferably inserted in the cardiac catheterization lab under fluoroscopic guidance. Bedside placement can be considered in very critical clinical situations.

  1. Begin by preparing the catheterization laboratory for the procedure. Prepare sterile drapes and chlorhexidine or povidone iodine, IABP control unit, IABP catheter, ultrasound for arterial access, 1% lidocaine for local anesthesia, micropuncture needle and wire, micropuncture sheath, 7-8.5 F arterial access sheath for....

Access restricted. Please log in or start a trial to view this content.

Results

Despite being used for many decades now, the evidence on IABP use has been controversial. Routine use of IABP in patients with AMI and cardiogenic shock is not recommended. The previous guidelines of the American Heart Association/American College of Cardiology (AHA/ACC) and the European Society of Cardiology (ESC) strongly recommended the use of the IABP in patients with AMI-associated cardiogenic shock (Class I B and Class I C) on the basis of pathophysiological considerations, non-randomized trials and registry data. .......

Access restricted. Please log in or start a trial to view this content.

Discussion

Mechanical circulatory support is a rapidly evolving field. Even with the arrival of newer support devices, IABP remains the most widely used and simplest to deploy mechanical circulatory support device available currently25. In this article we describe in detail, the procedure for percutaneous insertion of IABP, the indications, evidence, troubleshooting and complications. Despite conflicting evidence regarding the use of IABP in AMI-related cardiogenic shock, it remains the most widely used form.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Ganesh Gajanan MD has no conflicts of interests to declare

Emmanouil S. Brilakis, MD, PhD has the following disclosures : Consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; research support from Regeneron and Siemens. Shareholder: MHI Ventures.

Jolanta M. Siller-Matula, MD, PhD has the following disclosures: Lecture or consultant fees from AstraZeneca, Daiichi-Sankyo, Eli Lilly, Bayer and research grant from Roche Diagnostics;

Ronald L. Zolty, MD, PhD has the following disclosures: Consultant for Actelion, Bayer, United Therapeutics and Alnhylam

Poonam Velagapudi MD has no conflicts of interests to declare.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
IABP catheter and consoleGetingeSensation Plus
Micropuncture Introducer SetCook MedicalG48006
Sterile drapesHaylard
UltrasoundGE
LidocainePfizer

References

  1. Hochman, J. S., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. New England Journal of Medicine. 341 (9), 625-634 (1999).
  2. Thiele, H., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Cardiogenic ShockMechanical Circulatory SupportCounterpulsation TherapyFemoral Artery AccessSeldinger TechniqueDiastolic AugmentationHemodynamic SupportBalloon Pump InsertionSystemic Anticoagulation